Head-To-Head Review: Harrow (HROW) vs. The Competition

Harrow (NASDAQ:HROW – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Harrow to similar companies based on the strength of its institutional ownership, dividends, analyst recommendations, earnings, valuation, profitability and risk.

Institutional & Insider Ownership

72.8% of Harrow shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Harrow has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Harrow’s rivals have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Earnings & Valuation

This table compares Harrow and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Harrow $272.30 million -$5.14 million -41.32
Harrow Competitors $3.56 billion $3.18 billion 556.65

Harrow’s rivals have higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for Harrow and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow 2 1 6 0 2.44
Harrow Competitors 7850 13806 25844 1039 2.41

Harrow presently has a consensus target price of $66.20, indicating a potential upside of 105.42%. As a group, “Pharmaceuticals” companies have a potential upside of 27.51%. Given Harrow’s stronger consensus rating and higher possible upside, research analysts plainly believe Harrow is more favorable than its rivals.

Profitability

This table compares Harrow and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harrow -9.39% -69.81% -5.16%
Harrow Competitors -2,391.70% -206.08% -14.88%

Summary

Harrow beats its rivals on 8 of the 13 factors compared.

Harrow Company Profile

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.